Skip to main content
Journal cover image

Immunogenicity and protection conferred by a recombinant Mycobacterium marinum vaccine against Buruli ulcer

Publication ,  Journal Article
Hart, BE; Hale, LP; Lee, S
Published in: Trials in Vaccinology
January 1, 2016

Mycobacterium ulcerans (MU) infection causes the disfiguring necrotic skin disease, Buruli ulcer (BU). While vaccination with Mycobacterium bovis BCG provides nominal antigenic cross-reactivity for induction of immunity against experimental MU infection, a mycobacterial species with greater genetic homology to Mycobacterium ulcerans may serve as a richer source of cross-protective immunogens and lack the pathological features of MU-based vaccines. Mycobacterium marinum, a highly homologous genetic relative of MU, could be used to satisfy these criteria and, as such, we have generated a recombinant M. marinum strain expressing the immunodominant, protective MU-Ag85A. The immunogenicity and protection achieved by murine vaccination with this strain are superior to standard BCG vaccination and may serve as a foundation for developing more effective BU vaccines.

Duke Scholars

Published In

Trials in Vaccinology

DOI

EISSN

1879-4378

Publication Date

January 1, 2016

Volume

5

Start / End Page

88 / 91
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hart, B. E., Hale, L. P., & Lee, S. (2016). Immunogenicity and protection conferred by a recombinant Mycobacterium marinum vaccine against Buruli ulcer. Trials in Vaccinology, 5, 88–91. https://doi.org/10.1016/j.trivac.2016.04.001
Hart, B. E., L. P. Hale, and S. Lee. “Immunogenicity and protection conferred by a recombinant Mycobacterium marinum vaccine against Buruli ulcer.” Trials in Vaccinology 5 (January 1, 2016): 88–91. https://doi.org/10.1016/j.trivac.2016.04.001.
Hart, B. E., et al. “Immunogenicity and protection conferred by a recombinant Mycobacterium marinum vaccine against Buruli ulcer.” Trials in Vaccinology, vol. 5, Jan. 2016, pp. 88–91. Scopus, doi:10.1016/j.trivac.2016.04.001.
Journal cover image

Published In

Trials in Vaccinology

DOI

EISSN

1879-4378

Publication Date

January 1, 2016

Volume

5

Start / End Page

88 / 91